

# Effect of *Curcuma longa* and its derivatives, curcumin and curcuminoids on treatment of oral lichen planus: A systematic review of clinical evidence

# Mehrnaz Okhovatfard<sup>1</sup>, Hojat Rezazadeh<sup>2\*</sup>

Student Research Committee, Zahedan University of Medical Sciences, Zahedan. Iran
Student Research Committee, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran

\* Corresponding author's Email: hojat\_rezazadeh@yahoo.com

# ABSTRACT

Oral lichen planus (OLP) have become a serious problem for health system. *Curcuma longa* (*C. longa*) is recognized as a medicinal plant with numerous biological properties. Hence, this study was conducted to review the effect of *C. longa* and its derivatives, curcumin and curcuminoids in treatment of OLP. This study followed systematic review design. We used the guidelines of the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) statements. To perform this study, we searched Scopus, PubMed/Medline, Web of Science and Google Scholar tools using appropriate keywords including "oral lichen planus", " turmeric", " *Curcuma longa*", "curcumin" and "curcuminoids". The search was limited to English articles. In this study, all studies published until May 2023 were used. Of 76 identified articles from searching, 16 studies including 10 randomized controlled trials (RCTs), two case-controls and one case report were included in this systematic review. The sample size in these studies was 570 patients. Furthermore, most of these studies was done in India, Iran and USA. Taking together, turmeric and its derivatives curcumin and curcuminoids play important role in treatment of OLP. Indeed, its antioxidant and anti-inflammatory characteristics are probably responsible for therapeutic effects of turmeric and its derivatives. However, further studies are recommended for explaining therapeutic mechanisms of these compounds.

Keywords: Oral Lichen Planus, *Curcuma longa*, Turmeric, Curcumin, Curcuminoids. Article type: Review Article.

# INTRODUCTION

Oral lichen planus (OLP) is recognized as a chronic inflammatory disorder that lead to the involvement of the oral mucous membranes. OLP is characterized by abnormal keratinization of the mucous membranes inside the mouth (Alrashdan *et al.* 2016; Motahari *et al.* 2023; Manouchehri *et al.* 2023). Presence of reticular, erosive, or plaque-type lesions are the most common clinical features of OLP (Munde *et al.* 2013). The causes of OLP are still unknown, although several risk factors such as autoimmunity, using certain medications, infection, oral injuries, and allergy caused by dental materials play important roles in development of OLP (Nogueira *et al.* 2015). A considerable amount of literature has shown that female gender, smoking, alcohol and drug addiction are possible risk factors for OLP. Furthermore, a strong relationship between OLP and systemic diseases including diabetes mellitus, thyroid dysfunction, hepatitis C, and graft-versus-host disease has been reported in the literature (*Abe et al.* 2022). Globally, prevalence of OLP found as 1.01% (Nogueira *et al.* 2015). A primary concern of OLP is malignancy. However, it is estimated that 1.2% of patients with OLP represent malignancy (González-Moles *et al.* 2021). There are several pieces of evidence about the role of corticosteroids, photodynamic therapy, and their combination as therapeutic options for treatment of OLP (Sufiawati *et al.* 2022). Corticosteroids are the most potent anti-OLP agents known. The side effects

of corticosteroids have been extensively studied in recent years. Over the years, an enormous amount of studies have been carried out in an attempt to introduce alternative agents to reduce side effects caused by corticosteroids treatment (Han *et al.* 2017). Data from several studies have identified the role of inflammation and oxidative stress in development of OLP (Agha-Hosseini *et al.* 2012). Numerous studies have suggested that natural compounds represent therapeutic properties on various diseases (Ghuman *et al.* 2019). In recent years, there has been an increasing interest in the application of natural compounds such as medicinal plants and their active phytochemical constituents to treat OLP. An increased interest in the employment of turmeric as a therapeutic agent against various diseases has emerged in recent years (Amalraj *et al.* 2017). *Curcuma longa* (*C. longa*) also known as turmeric is an edible plant with medicinal properties. A key aspect of turmeric is its numerous therapeutic properties. Antioxidant, anti-microbial, anti-inflammatory, and anticancer are reported as its most widely-investigated therapeutic effects (Beiranvand & Alizadeh 2019; Amiri *et al.* 2023). Curcumin and curcuminoids are well known components of *C. longa*. Quite recently, considerable attention has been paid to plentiful biological effects of curcumin and curcuminoids (Kocaadam *et al.* 2017). Ample evidence exists to support the hypothesis that *C. longa*, curcumin and curcuminoids represent therapeutic effect on OLP (Chainani-Wu *et al.* 2012). The purpose of this systematic review paper is to review recent studies about the effects of turmeric and its derivatives, curcumin and curcuminoids in treatment of OLP.

## MATERIALS AND METHODS

## Database and search strategies

This study followed the guidelines of the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) statements. To conduct this systematic review, literature search was carried out through Scopus, PubMed/Medline, Web of Science and Google Scholar tools. First of all, appropriate keywords were selected as follow: "oral lichen planus"," turmeric"," *Curcuma longa*", "curcumin" and "curcuminoids". The systematic search was performed in English documents. In this study, all studies published until May 2023 were used. Our search was limited to studies with clinical evidence such as randomized clinical trial, Case-control, cohort studies, and case report (Fig. 1).

#### **Data extraction**

We extracted data as follow: type of treatment, authors, publication year, study design, sample size, group design, gender of patients, dose of treatment, preparation method, form of administration, duration of follow up, and outcomes (Amiri *et al.* 2023).



Fig. 1. Flowchart of study selection.

# RESULTS

Our search leads to extraction of 76 articles from databases. After removing duplicates, the results of 16 studies were extracted. As shown in Table 1, a total of 570 patients were studied in these articles. We found that 10 studies were clinical trials (Chainani-Wu *et al.* 2012; Singh *et al.* 2013; Kia *et al.* 2015; Kia SJ *et al.* 2015; Bakhshi *et al.* 2020;

Khaitan *et al.* 2022; Ghobadi *et al.* 2022), two were case-controls (Nosratzehi *et al.* 2018; Naik *et al.* 2021) and one was case report (Prasad *et al.* 2014). The results showed that 7 studies was conducted in India (Singh *et al.* 2013; Thomas *et al.* 2017; Naik *et al.* 2019), 7 in Iran (Chainani-Wu *et al.* 2012; Kia SJ *et al.* 2015; Kia *et al.* 2015; Bakhshi *et al.* 2020; Khaitan *et al.* 2022; Ghobadi *et al.* 2022) and 2 in USA (Chainani-Wu *et al.* 2007). Our findings revealed that most of studies used turmeric, Curcumin and Curcuminoids in the form of oral (n = 9) and other studies administrated treatment in the form of topical (n = 7).

#### DISCUSSION

This study provides an overview of therapeutic effects of turmeric and its derivatives curcumin and curcuminoids on OLP. Numerous scholars found evidence that turmeric and its derivatives such as curcumin and curcuminoids play important roles in treatment of OLP (Singh et al. 2013; Bakhshi et al. 2020). The results of this systematic review revealed that C. longa as a promising medicinal plants in traditional medicine has a great therapeutic effect on OLP. There are several pieces of evidence about numerous therapeutic effects of C. longa on various diseases (Razavi et al. 2021; Tang et al. 2021; Jyotirmayee et al. 2022). It is generally accepted wisdom that C. longa is an effective agent for treatment of oral diseases (Umapathy et al. 2022). Several studies have examined the effect of C. longa in treatment of OLP (Singh et al. 2013). For instance, in a study conducted by Kia SJ et al. (2015) the results demonstrated that treatment with C. longa through oral administration of ethanolic extract of root can induce reduction in VAS score, pain and thongprasom score. The authors also observed that complete remission occurred in some of patients. In another similar study, Singh and colleagues reported that treatment of OLP patients with extract of turmeric in form of topical improved clinical symptoms such as burning sensation, redness, ulceration and decreased thongprasom sign score and VAS score (Singh et al. 2013). It has been accepted that OLP is an oral disease that is characterized by Tcell mediated inflammatory responses and imbalance between oxidative stress and endogenous antioxidants (Abe et al. 2022). C. longa is a medicinal plant with several biological properties such as antioxidant and anti-inflammatory effects. A growing body of evidence has demonstrated that C. longa is recognized as a rich source of active phytochemical constituents with potent antioxidant and anti-inflammatory effects including curcumin and curcuminoids (Sabir et al. 2020). It is possible that phytochemical compounds in C. longa neutralize inflammatory response and oxidative status in OLP patients through their antioxidant and anti-inflammatory effects (Khaitan et al. 2022). Curcumin is an active ingredient with numerous therapeutic effects. It has been suggested that curcumin could alleviate symptoms caused by OLP. Ghobadi et al. (2022) reported that oral capsule contain nanocurcumin could use for pain relief and decreasing appearance of lesions and burning sensation. Another similar study conducted by Khaitan T et al. (2022) revealed that using oral gel contain 10 mg g<sup>-1</sup> curcumin in form of topical paste treated OLP patients through reduction in pain, burning sensation score through VAS scoring. They also concluded that curcumin treatment decreased the size and severity of the lesions (Khaitan et al. 2022). Curcumin is a well-known antioxidant compound that is recognized by its free radical scavenging property. Since the imbalance between oxidative stress and antioxidants plays an important role in the occurrence of lesions caused by OLP, using antioxidants such as curcumin plays an important role in improving the damage caused by OLP (Meng et al. 2013). On the other hand, inflammation and inflammatory responses are the most effective mechanisms for the development of lesions in OLP patients. Therefore, the administration of anti-inflammatory compounds with natural origin such as curcumin works well in eliminating these lesions (Meng et al. 2013). Curcuminoids constitute an important part of the chemical compounds in C. longa. Demethoxycurcumin and bisdemethoxycurcumin are most studied curcuminoids present in C. longa. Numerous biological properties are the prominent features of these compounds (Amalraj et al. 2017). The application of demethoxycurcumin and bisdemethoxycurcumin in the treatment of oral diseases including OLP is one of the other functions of these compounds. In a randomized, placebo-controlled, double-blind clinical trial conducted by Chainani Wu et al. (2007) the results highlighted that oral consumption of curcuminoids including demethoxycurcumin and bisdemethoxycurcumin could treat OLP through decreasing erythema scores, ulceration scores, VAS scores, and NRS scores.

Treatm	Author	Со	Study	Ν	Group Design	Dosage	Preparat	Form	Follow up	Key Findings
ent	s and	unt	Design				ion	of		
	publica	ry						applic		
	tion							ation		
	year									
	(Ref)									
С.	Kia et	Iran	А	50	Group 1	5%	Ethanolic	Oral	four weeks	Treatment with C. longa
longa	al.		Random	patients	(intervention group):		extract of			decreased VAS score, pain
	(2015)		ized,	(36	received curcumin		root			and Thongprasom score.
			Controll	females	once a day $(n = 25)$					Complete remission was also
			ed	and 14	Group 2 (control					observed in some of patients.
			Clinical	males)	group): received					
			Trial		0.1% triamcinolone					
					(n = 25)					
	Singh et	Indi	A pilot	10	Group 1: Treatment	-	Extract	Local	3 months (1 <sup>st</sup>	Turmeric extract improved
	al. 2013	а	study	patients	group		of	applica	week, 2 <sup>nd</sup> week	clinical symptoms of 9
							turmeric	tion in	4th week, and	patients completely.
								the	3 <sup>rd</sup> month)	All of symptoms of OLP
								ointme		including burning sensation,
								nt		redness, and ulceration were
								form		removed in the 3 <sup>rd</sup> month of
										treatment.
										Treatment with C. longa
										extract reduced thongprasom
										sign score (0-1) in patients
										after 3 months.
										Furthermore, VAS decreased
										in treated patients with
										turmeric after 3 months.

Table 1. Summary of available literature on the effect of turmeric, Curcumin and Curcuminoids in Treatment of OLP.

Curcu	Khaitan	Indi	A non-	40	Group A	Curenext	-	Topica	First follow-	Curcumin played potential
min	et al.	а	randomi	patients	(intervention group):	oral gel		1 paste	up: after 4	role in the treatment of OLP.
	(2022)		zed	(14	patients who	containing		-	weeks	Curcumin could reduce pain
			controll	males	received curcumin	10 mg g <sup>-1</sup>			Second	burning sensation score
			ed trial	and 26	oral gel and a	curcumin			follow-up:	through VAS scoring.
				females	multivitamin				after 12 weeks	Treatment with curcumin
				)	capsule containing					significantly decreased REU
					zinc (n = 20)					score.
					Group B (control					Furthermore, the size and
					group): patients who					severity of the lesion
					received					decreased after 4 weeks and
					multivitamin					12 weeks.
					containing zinc only					
					(n = 20)					
	Ghobad	Iran	А	28	Group A	Nanocurc	Nano-	Oral	1 month	Treatment with
	i et al.		Single	patients	(intervention group):	umin (80	Micellar	capsul		nanocurcumin decreased pain
	(2022)		Blind	(15	patients who	mg)	Soft gel	e		severity, appearance of
			Random	females	received		capsule			lesions and burning.
			ized	and 13	nanocurcumin					
			Controll	males)	(n=29)					
			ed		Group B (placebo					
			Clinical		group): patients who					
			Trial		received					
					Prednisolone 10mg					
					(n=28)					
	Naik <i>et</i>	Indi	-	68	Group I: received	-	Curenext	Topica	First follow-	Curcumin show effectiveness
	al.	а		patients	Curenext oral gel		oral gel	1	up: after 10	on treatment of OLP
	(2021)				was prescribed for			applica	days	especially in combination to
					15 minutes, three			tion	Second	prednisone.
					times a day (n=34)				follow-up:	Indeed, curcumin particularly
					Group II: received				after 20 days	in combination to prednisone
					prednisone and					decreased reticulation score,
					curenext oral gel for					erosion score, and VAS
					15 minutes, three					score.
					times a day $(n = 34)$					

Kia et	Iran	А	57 (48	Group A (trial	Nanocurc	Nano-	Oral	1 month	Administration of
al.		randomi	females	group): patients who	umin	Micellar	capsul		nanocurcumin decreased pain
(2020)		zed	and 9	received	80mg	Soft gel	e		severity and burning
		double-	males)	nanocurcumin (n =		capsule			sensation through VAS score.
		blinded		29)					The results of Thongprasom
		clinical		Group B (control					scale scoring showed that
		trial		group): patients who					treatment with nanocurcumin
				received					decreased OLP lesions.
				Prednisolone 10 mg					
				(n = 28)					
Naik et	Indi	A Case	60	Group 1: received	-	Curenext	Topica	First follow-	Combined treatment with
al.	а	Controll	patients	curenext gel for 15		oral gel	1	up: after 10	curenext gel and prednisone
(2020)		ed	(29	mins, three times a			applica	days	play role in reduction of pain
		Compar	females	day (n=30)			tion	Second	reticulation, and erosion
		ative	and 31	Group 2: received				follow-up:	caused by OLP.
		Study	males)	prednisone and				after 20 days	
				curenext oral gel for					
				15 minutes, three					
				times a day $(n = 30)$					
Bakhshi	Iran	Random	31	Group 1: received	1%	Nanomic	Topica	1 month	Mean REU score
et al.		ized	patients	0.1% triamcinolone		elle	1		significantly decreased in
(2020)		Double-	(24	mouth rinse + %1			applica		patients treated with
		Blind	females	nanocurcumin gel			tion		nanocurcumin.
		Placebo	and 7	(n=14)					
		Controll	males)	Group 2: received					
		ed		0.1% triamcinolone					
		Clinical		mouth rinse +					
		Trial		placebo gel $(n = 17)$					
Nosratz	Iran	Case-	40	Group 1 (case	-	Mucoadh	Topica	3 months	Curcumin showed
ehi et		control	patients	group): received		esive	1		therapeutic effect on OLP via
al.		study	(26	curcumin		paste			decreasing lesion size and
(2018)			females	mucoadhesive paste					pain severity.
			and 14	thrice daily after					
			males)	meals $(n = 20)$					

					Group 2 (control					· · · · · · · · · · · · · · · · · · ·
					group): received					
					0.1% beta-					
					methasone local					
					steroid lotion (n =					
					20)					
	Kia <i>et</i>	Iran	A pilot	10	Treatment group	80 mg	Curcumi	Oral	4 weeks	After treatment with
	al.		clinical	patients	received curcumin		n	capsul		curcumin, pain and lesions
	(2017)		trial	(9	capsules 80 mg once		capsules	e		were improved in most of the
	· /		interven	females	a dav		1			patients.
			tion	and 1						I
			study	males)						
ŀ	Thomas	Indi	An	75	Group 1: received	10 mg	Curopovt	oral	3 months	It has been observed that
	at al	niui	interror	notionto	0.1% triamainalana	10 mg	oral gal	gol	5 monuis	auroumin treatment play
	(2017)	a	tion	(74.60)			oral ger	gei		significant role in reduction
	(2017)			(74.0%)	Constant					significant fole in reduction
			study	were	Group 2: received					in erythema, ulceration, and
				females	curcumin three					burning sensation in patients
				and	times a day					with OLP.
				25.4%	Group 3: received					
				were	curcumin six times a					
				males)	day					
	Amirch	Iran	А	20	Group 1	2000 mg	Tablets	Oral	Four weeks	Atrophic and erosive lesions
	agh-		Random	patients	(intervention group):	day-1				improved following
	maghi		ized	(13	received curcumin					curcumin treatment.
	et al.		Controll	females	(n = 12)					Furthermore, a significant
	(2016)		ed Trial	and 7	Group 2 (control					reduction was observed in the
	· /			males)	group): received					VAS score and the
				,	placebo $(n = 8)$					Thongprasom score after
					F					treatment with curcumin
-	Keshari	Indi	А	27	Group 1 (study	-	Commer	topical	First follow-	Treatment with curcumin
	et al.	а	randomi	patients	group): received		cially	curcu	up: after 7	ointment significantly
	(2015)		zed	(16	curcumin ointment		available	min	days	decreased pain, erythema,
	. /		controll	males	thrice daily $(n = 15)$			ointme		and ulceration scores.
			ed-trial	and 11				nt		
		1			1	1	1	1		

				females	Group 2 (control				Second	
				)	group): received				follow-up:	
				/	triamcinolone				after 15 days	
					acetonide $0.1\%$ (n –				ulter 15 duys	
					12					
	D 1	T 1'	0	1	12)	D	0 1	0.1	2 1	
	Prasad	Indi	Case	1	-	Patient	Capsule	Oral	3 months	OLP response to curcumin
	et al.	а	report	patient		received				completely.
	(2014)			(22-		500 mg				
				year-old		two times				
				and		a day for a				
				male)		month.				
						After				
						three				
						weeks,				
						patient				
						received				
						500 mg				
						once a dav				
						curcumin				
						cansule				
						for 2				
						weeks				
						250 mg				
						250 mg				
						for the last				
						for the fast				
0	<u> </u>	ЦG		20	0 1	two weeks	<b>TD</b> 11 /	0 1		
Curcum	Chainan	US	A	20	Group I	6000 mg	I ablets	Oral	2 weeks	Curcuminoids play important
inoid	1 Wu <i>et</i>	А	randomi	patients	(intervention group):	day				role in improvement of OLP
(demeth	al.		zeddoub	(13	received					signs. Treatment with
oxycurc	(2012)		le-blind,	females	curcuminoids					curcuminoids could decrease
umin,			placebo	and 7	(n=10)					erythema and ulceration
bisdeme			-	males)	Group 2 (control					through decreasing NRS and
thoxycu			controll		group): received					MOMI scores.
rcumin)			ed		placebo (n = $10$ )					

		clinical trial							
Chainan i Wu <i>et</i> <i>al.</i> (2007)	US A	A randomi zed, placebo - controll ed, double- blind	33	Group 1 (intervention group): received prednisone (60 mg day <sup>-1</sup> ) + curcuminoids (n = 16) Group 2 (control group): received prednisone (60 mg	2000 mg day <sup>-1</sup>	Capsules	Oral	7 weeks	Administration of curcuminoids showed a better outcomes. Treatment with curcuminoids dropped erythema scores, ulceration scores, VAS scores, and NRS scores.
		trial		= 17)					

Note: VAS: Visual analogue scale; REU: reticulation/keratosis, erythema, and ulceration; NRS: Numerical Rating Scale; MOMI: Modified Oral Mucositis Index

It has been observed that curcuminoids exert their therapeutic effects on OLP through antioxidant and antiinflammatory properties. A number of limitations may influence the results. Some of these limitations in our systematic review are as follows: the quality of included study and different patient populations.

## CONCLUSION

Based on the results of mentioned studies, treatment of OLP patients by turmeric and its derivatives curcumin and curcuminoids can reduce signs and symptoms caused by OLP including, severity of pain, the size and appearance of lesions and burning sensations. Furthermore, findings revealed that *C. longa* and its derivatives curcumin and curcuminoids in combination with corticosteroids such as prednisolone could exert better therapeutic function against OLP. Indeed, the numerous biological properties of turmeric and its derivatives curcumin and curcuminoids such as antioxidant and anti-inflammatory effects have raised this compound as an effective factor in the treatment of OLP. However, more studies with higher accuracy can confirm this issue.

# CONFLICT OF INTEREST

There are no conflicts of interest to declare.

#### REFERENCES

- Abe, A, Ito Y, Hayashi H, Momokita M, Taniguchi S & Nakayama, A 2022, Evaluation of the classification and clinical characteristics of oral lichen planus and its treatment effect in different clinical types: a retrospective study. *Advances in Oral and Maxillofacial Surgery*, 8:100369.
- Agha-Hosseini, F, Mirzaii-Dizgah, I, Farmanbar, N & Abdollahi, M 2012, Oxidative stress status and DNA damage in saliva of human subjects with oral lichen planus and oral squamous cell carcinoma. *Journal of Oral Pathology & Medicine*, 41: 736-740.
- Alrashdan, MS, Cirillo, N, McCullough, M, 2019, Oral lichen planus: a literature review and update. *Archives of Dermatological Research*, 308: 539-551.
- Amalraj, A, Pius, A, Gopi, S, Gopi, S 2016, Biological activities of curcuminoids, other biomolecules from turmeric and their derivatives: A review. *Journal of Traditional and Complementary Medicine*, 7: 205-233. DOI: 10.1016/j.jtcme.2016.05.005.
- Amirchaghmaghi, M, Pakfetrat, A, Delavarian, Z, Ghalavani, H & Ghazi A 2016, Evaluation of the efficacy of curcumin in the treatment of oral lichen planus: a randomized controlled trial. *Journal of Clinical and Diagnostic Research*, 10(5): ZC134-ZC137, DOI: 10.7860/JCDR/2016/16338.7870
- Amiri, MM, Fayyadh, SH, Parra, RMR, Al-Khafaji, AHD, Abosaooda, M, Darvishi, M et al. 2023, Role of selective cyclooxygenase-2 inhibitors in renal colic pain reduction and improvement: A systematic review of clinical trials. Advancements in Life Sciences, 9(4):446-452.
- Amiri MM, Garnida Y, Almulla AF, Abduljabbar AS, Jalil AT, Mazaheri Y, Ebrahimi Y, Shariatifar N 2023, Herbal therapy for hemorrhoids: An overview of medicinal plants affecting hemorrhoids. *Advancements in Life Sciences*, 10: 22-28.
- Bakhshi, M, Gholami, S, Mahboubi, A, Jaafari, MR, Namdari, M 2020, Combination therapy with 1% nanocurcumin gel and 0.1% triamcinolone acetonide mouth rinse for oral lichen planus: A randomized double-blind placebo controlled clinical trial. *Dermatology Research and Practice*. 2(3): 4.
- Beiranvand F, Alizadeh M 2019, Plants for Remedies of Diabetes Mellitus in Iran. *Plant Biotechnology Persa*, 1 (1): 36-38.
- Chainani-Wu, N, Madden, E, Lozada-Nur, F, Silverman, Jr S 2012, High-dose curcuminoids are efficacious in the reduction in symptoms and signs of oral lichen planus. *Journal of the American Academy of Dermatology*, 66: 752-760.
- Chainani-Wu, N, Silverman, Jr S, Reingold, A, Bostrom, A, Mc Culloch, C, Lozada-Nur, F, *et al.* 2007, A randomized, placebo-controlled, double-blind clinical trial of curcuminoids in oral lichen planus. *Phytomedicine*, 14: 437-446.
- Ghobadi, N, Lesan, S & Khatibi, M 2022, Effect of curcumin on oral lichen planus: A single blind randomized controlled clinical trial. *Journal of Mazandaran University of Medical Sciences*, 32(211): 37-48. http://jmums.mazums.ac.ir/article-1-17434-en.html

- Ghuman, S, Ncube, B, Finnie, J, McGaw, L, Njoya, EM, Coopoosamy, R *et al.* 2019, Antioxidant, antiinflammatory and wound healing properties of medicinal plant extracts used to treat wounds and dermatological disorders. *South African Journal of Botany*, 126:232-40.
- González-Moles MÁ, Warnakulasuriya S, González-Ruiz I, González-Ruiz L, Ayen A, Lenouvel D, et al. 2021, Worldwide prevalence of oral lichen planus: A systematic review and meta-analysis. Oral diseases, 27: 813-828.
- Han, X, Zhang, J, Tan, Y & Zhou G 2017, Probiotics: A non-conventional therapy for oral lichen planus. *Archives* of Oral Biology, 81: 90-96.
- Jyotirmayee, B & Mahalik, G 2022, A review on selected pharmacological activities of *Curcuma longa* L. *International Journal of Food Properties*, 25: 1377-1398.
- Keshari, D, Patil, K & Mahima, V 2015, Efficacy of topical curcumin in the management of oral lichen planus: A randomized controlled-trial. *Journal of Advanced Clinical and Research Insights*, 2: 197-203.
- Khaitan, T, Kabiraj, A, Sinha, DK, Ranjan, R & Singh, R 2022, *Curcuma longa* in the treatment of symptomatic oral lichen planus: A non-randomized controlled trial. *Indian Journal of Dermatology*, 67: 478.
- Kia, SJ, Basirat, M & Estakhr, L 2017, The effect of oral curcumin on pain and clinical appearance of oral lichen planus. *Journal of Dentomaxillofacial Science*, 6: 1-7.
- Kia, SJ, Basirat, M, Mortezaie, T & Moosavi, MS 2020, Comparison of oral nano-curcumin with oral prednisolone on oral lichen planus: A randomized double-blinded clinical trial. *BMC Complementary Medicine and Therapies*, 20: 1-7.
- Kia, SJ, Shirazian, S, Mansourian, A, Fard, LK & Ashnagar, S 2015, Comparative efficacy of topical curcumin and triamcinolone for oral lichen planus: a randomized, controlled clinical trial. *Journal of Dentistry*, 12: 789.
- Kocaadam, B & Şanlier, N 2017, Curcumin, an active component of turmeric (*Curcuma longa*), and its effects on health. *Critical Reviews in Food Science and Nutrition*, 57: 2889-2895.
- Meng, B, Li, J & Cao, H 2013, Antioxidant and anti-inflammatory activities of curcumin on diabetes mellitus and its complications. *Current pharmaceutical design*, 19: 2101-2113.
- Motahari, P, Daliraan, R & Poorzare, S 2023, Comparing the effects of lycopene and corticosteroids on oral lichen planus: a systematic review and meta-analysis. *Journal of Herbmed Pharmacology*, 12: 337-343. DOI: 10.34172 /jhp.2023.36.
- Munde, AD, Karle, RR, Wankhede, PK, Shaikh, SS & Kulkurni M 2013, Demographic and clinical profile of oral lichen planus: A retrospective study. *Contemporary Clinical Dentistry*, 4:181.
- Naik R, Nazneen L, Dhoble A, Thombre A, Saxena U, Kosta S 2021, Curcumin alone and curcumin with prednisone in management Oral Lichen Planus patients. *European Journal of Molecular & Clinical Medicine*, 8: 3784-3788.
- Naik, SR, Gupta, P, Ashok, L, Khaitan, T & Shukla, AK 2019, A novel mixture of curcumin paste and prednisolone for treating oral lichen planus: A case controlled comparative study. *Journal of Indian Academy* of Oral Medicine and Radiology, 31: 286-292.
- Nogueira, PA, Carneiro, S, Ramos-e-Silva, M 2015, Oral lichen planus: an update on its pathogenesis. *International Journal of Dermatology*, 54: 1005-1010, DOI: 10.1111/ijd.12918.
- Nosratzehi, T, Arbabi-Kalati, F, Hamishehkar, H & Bagheri, S 2018, Comparison of the effects of curcumin mucoadhesive paste and local corticosteroid on the treatment of erosive oral lichen planus lesions. *Journal of the National Medical Association*, 110: 92-97. DOI: 10.1016/j.jnma.2017.01.011.
- Prasad, S, Solanki, S, Chinmaya, B, Tandon, S & Ashwini B 2014, The magic of herbal curcumin therapy in recurrent oral lichen planus. *American Journal of Ethnomedicine*, 1: 96-101.
- Razavi, BM, Ghasemzadeh Rahbardar, M & Hosseinzadeh, H 2021, A review of therapeutic potentials of turmeric (*Curcuma longa*) and its active constituent, curcumin, on inflammatory disorders, pain, and their related patents. *Phytotherapy Research*, 35:6489-64513.
- Sabir, S, Zeb, A, Mahmood, M, Abbas, S, Ahmad, Z & Iqbal, N 2020, Phytochemical analysis and biological activities of ethanolic extract of *Curcuma longa* rhizome. *Brazilian Journal of Biology*, 81: 737-740.
- Singh, V, Pal, M, Gupta, S, Tiwari, S, Malkunj, e L & Das, S 2013, Turmeric: A new treatment option for lichen planus: A pilot study. *National journal of maxillofacial surgery*, 4: 198.

- Sufiawati, I, Christine, H & Drakel, FF 2022, The effectiveness of corticosteroid and diode laser combination therapy in the treatment of severe oral lichen planus: A case report. *Journal of International Dental and Medical Research*, 15: 312-314.
- Tang, W, Du, M, Zhang, S & Jiang, H 2021, Therapeutic effect of curcumin on oral diseases: A literature review. *Phytotherapy Research*, 35: 2287-2295.
- Thomas, AE, Varma, B, Kurup, S, Jose, R, Chandy, ML, Kumar, SP *et al.* 2017, Evaluation of efficacy of 1% curcuminoids as local application in management of oral lichen planus–interventional study. *Journal of Clinical and Diagnostic Research*, 11: ZC89.
- Umapathy, VR, Swamikannu, B, Jones, S, Kiran, M, Lell, T, Mayasa, V *et al.* 2022, Effects of turmeric (*Curcuma longa*) on oral health. *Bioinformation*, 18: 538.
- Zheng, QT, Yang, ZH, Yu, LY, Ren, YY, Huang, QX, Liu, Q, *et al.* 2017, Synthesis and antioxidant activity of curcumin analogs. *Journal of Asian Natural Products Research*, 19: 489-503.